Roche's chairman still predicts that diagnostic products will be affected by US tariffs.

Roche Group Chairman Severin Schwan stated on Saturday that Roche expects its agreement with the US government to protect its drugs from the impact of the current round of import tariffs, but its diagnostic division still faces risks and may face new tariffs after the initial 150-day deadline. Schwan said that Roche's diagnostic division had sales close to 14 billion Swiss francs in 2025, with most of its tests and instruments exported from Switzerland and other European countries to the United States.